PDF(715 KB)
年龄、性别、族别及联合用药对新疆癫痫患儿左乙拉西坦血药浓度的影响
赵婷, 李红健, 王婷婷, 孙力, 于鲁海, 蒋玉凤, 孙岩
中国医院药学杂志 ›› 2017, Vol. 37 ›› Issue (12) : 1174-1178.
PDF(715 KB)
PDF(715 KB)
年龄、性别、族别及联合用药对新疆癫痫患儿左乙拉西坦血药浓度的影响
Influences of age, gender, ethnical group and drug combination on levetiracetam plasma concentration in Xinjiang pediatric patients with epilepsy
目的：探讨年龄、性别、族别及合并用药对新疆癫痫患儿左乙拉西坦（LEV）血药浓度的影响。方法：采用超高效液相色谱法（UPLC）测定110例癫痫患儿LEV的稳态血药浓度，并记录患儿的年龄、性别、族别、给药剂量及合并用药等基本信息，利用SPSS 17.0软件进行数据分析。结果：在每千克体质量给药剂量无差异的情况下，不同年龄、性别和族别癫痫患儿LEV的CDR值的差异无统计学意义（P>0.05）；LEV合并丙戊酸钠（VPA）或LEV合并VPA、托吡酯（TPM）后的LEV给药剂量和血药浓度呈显著正相关（r>0.6，P<0.05），LEV单药及LEV合并VPA、奥卡西平（OXC）或拉莫三嗪（LTG）后的LEV给药剂量和血药浓度不相关。结论：LEV在儿童体内消除速率快，半衰期短，用药依从性差，且癫痫患儿需长期服药，因此在儿科临床用药时，通过对LEV的血药浓度进行监测，可为患儿提高疗效和服药依从性提供依据。
OBJECTIVE To evaluate the influences of age, gender, ethnical group and drug combination on levetiracetam plasma concentration in Xinjiang pediatric patients with epilepsy.METHODS Totally 110 children with epilepsy were collected and were treated by levetiracetam. The concentration of levetiracetam was determined by ultra performance liquid chromatography (UPLC). Plasma concentrations, age, gender, ethnical group and drug combination were analyzed by SPSS 17.0 software.RESULTS After 8-46 mg·kg-1·d-1 of levetiracetam was administered, no statistically significant difference was observed in CDR of age, gender or ethnical group (P>0.05). Drug dose and plasma concentration were positively correlated for LEV + VPA or LEV + VPA + TPM (r>0.6, P<0.05), but negative for LEV alone or LEV + VPA + OXC or LTG + LEV.CONCLUSION LEV in children has fast elimination rate, short half life, poor medication adherence, but children with epilepsy should be medicated for long term. Therefore, monitoring on LEV concentration can provide the basis to improve efficacy and medication adherence.
新疆 / 癫痫 / 超高效液相色谱 / 左乙拉西坦 / 血药浓度 {{custom_keyword}} /
Xinjiang / epilepsy / ultra performance liquid chromatography (UPLC) / levetiracetam / plasma concentration {{custom_keyword}} /
[1] 沈晓明,王卫平.儿科学[M].7版.北京:人民卫生出版社,2008:390-391.
[2] 王宇卉.解读"中国抗癫痫药物治疗专家共识(2011)"[J].世界临床药物,2012,33(1):63-64, 后插1-后插3.
[3] Crepeau AZ, Treiman DM. Levetiracetam:a comprehensive review[J]. Expert Rev Neurother, 2010, 10(2):159-171.
[4] Perucca E, Gidal BE, Balt s E. Effects of antiepileptic comedication on levetiracetam pharmacokinetics:a pooled analysis of data from randomized adjunctive therapy trials[J]. Epilepsy Res, 2003, 53(1/2):47-56.
[5] Patsalos PN. Clinical pharmacokinetics of levetiracetam[J]. Clin Pharmacokinet, 2004, 43(11):707-724.
[6] Gidal BE, Balt s E, Otoul C, et al. Effect of levetiracetam on the pharmacokinetics of adjunctive antiepileptic drugs:a pooled analysis of data from randomized clinical trials[J]. Epilepsy Res, 2005, 64(1/2):1-11.
[7] Toublanc N, Lacroix B, Yamamoto J. Development of an integrated population pharmacokinetic model for oral levetiracetam in populations of various Ages and ethnicities[J]. Drug Metab Pharmacokinet, 2014, 29(1):61-68.
[8] 包丹丹,张桢.824例(1495例次)左乙拉西坦血药浓度监测结果回顾性分析[J].中国当代医药,2016,23(23):123-125.
[9] Patsalos PN, Berry DJ, Bourgeois BF, et al. Antiepileptic drugs——best practice guidelines for therapeutic drug monitoring:a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies[J]. Epilepsia, 2008, 49(7):1239-1276.
[10] Contin M, Mohamed S, Albani F, et al. Simple and validated HPLC-UV analysis of levetiracetam in deproteinized plasma of patients with epilepsy[J]. J Chromatogr B Analyt Technol Biomed Life Sci, 2008, 873(1):129-132.
[11] 王颖慧,魏敏吉,王云秀,等.高效液相色谱法测定左乙拉西坦血药浓度[J].儿科药学杂志,2010,16(4):34-36.
[12] Contin M, Mohamed S, Albani F, et al. Simple and validated HPLC-UV analysis of levetiracetam in deproteinized plasma of patients with epilepsy[J]. J Chromatogr B Analyt Technol Biomed Life Sci, 2008, 873(1):129-132.
[13] 王婷婷,李红健,贾莉,等.维吾尔族癫痫患儿奥卡西平活性代谢产物血药浓度监测分析[J].中国医院药学杂志,2016,36(8):644-646.
[14] 沈晓明,王卫平.儿科学[M].7版.北京:人民卫生出版社,2008:390-391.
[15] 王俊,张华年,陈渝军,等.儿童体内左乙拉西坦血药浓度与单药治疗临床疗效的关系[J].中国医院药学杂志,2016,36(6):476-480.
[16] 《中国国家处方集》编委会.中国国家处方集化学药品与生物制品卷·儿童版[M].北京:人民军医出版社,2013:80.
[17] Lancelin F, Franchon E, Kraoui L, et al. Therapeutic drug monitoring of levetirace-tam by high-performance liquid chromatography with photodiode array ultraviolet detecti-on:preliminary observations on correlation between plasma concentration and clinical respo-nse in patients with refractory epilepsy[J]. Ther Drug Monit, 2007, 29(5):576-583.
[18] Juenke JM, Brown PI, Urry FM. Analysis of levetiracetam and zonisamide in plasma and serum by HPLC[J]. Clin Chem, 2002, 48(6, 2, S):A44-A45.
[19] Folland C, Moriarty G. Clinical experience of levetiracetam(LEV)in refractory adult epilepsy patient[J]. Epilepsia, 2002, 43(Suppl7):192.
[20] Iwasaki T, Toki T, Nonoda Y, et al. The efficacy of levetiracetam for focal seizures and its blood seizures and its blood level in children[J]. Brain Dev, 2015, 37(8):773-779.
[21] De Smedt T, Raedt R, Vonck K, et al. Levetiracetam:part Ⅱ, the clinical profile of a novel anticonvulsant drug[J]. CNS Drug Rev, 2007, 13(1):57-78.
[22] Chhun S, Jullien V, Rey E, et al. Population pharmacokinetics of levetiracetam and dosing recommendation in children with epilepsy[J]. Epilepsia, 2009, 50(5):1150-1157.
[23] Otoul C, De Smedt H, Stockis A. Lack of pharmacokinetic interaction of levetiracetam on carbamazepine, valproic acid, topiramate, and lamotrigine in children with epilepsy[J]. Epilepsia, 2007, 48(11):2111-2115.
[24] Arroyo S, Crawford P. Safety profile of levetiracetam[J]. Epilep-ticDis, 2003, 5(1):57-63.
[25] Patsalos PN, Berry DJ, Bourgeois BF, et al. Antiepileptic drugs——best practice guidelines for therapeutic drug monitoring:a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies[J]. Epilepsia, 2008, 49(7):1239-1276.
[26] 汪洋,张华年,徐华,等.左乙拉西坦在癫痫患儿中的群体药动学研究[J].中国新药与临床杂志,2015,33(3):184-190.
"CAAE癫痫科研基金-UCB基金"资助项目（编号：201407）
/
| 〈 |
|
〉 |
